GlassScriptPhysician profile
Stephan Kowalyk
NPI 1457458168
$590,966.29
in general payments reported to CMS, 2019-2025
68 companies · $82K in 2025
The $82K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $67K · 2021: $77K · 2022: $119K · 2023: $84K · 2024: $69K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $148K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $39K · Travel and Lodging: $26K · Food and Beverage: $19K · Consulting Fee: $3,415 · Education: $65.74 · Gift: $59.40 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,785.37 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $38,545.00 |
| Travel and Lodging | $25,886.01 |
| Food and Beverage | $19,199.78 |
| Consulting Fee | $3,415.00 |
| Education | $65.74 |
| Gift | $59.40 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $178,040.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $119,402.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $70,024.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $54,497.68 | 2019-2024 | Farxiga, Lokelma |
| Dexcom, INC. | $40,120.69 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,563.33 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $25,076.78 | 2021-2025 | |
| Abbott Laboratories | $14,453.76 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre |
| Mannkind Corporation | $12,736.85 | 2022-2025 | V-Go, Afrezza |
| Janssen Pharmaceuticals, INC | $12,484.29 | 2019-2020 | |
| Valeritas, INC. | $10,524.94 | 2019 | |
| Cequr Corporation | $8,638.66 | 2022-2025 | Cequr Simplicity |
| Zealand Pharma US, INC. | $4,355.30 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $3,365.56 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Medtronic Minimed, INC. | $1,790.51 | 2019-2020 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $937.61 | 2019-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $795.61 | 2019-2025 | Unithroid |
| Amarin Pharma, INC. | $766.92 | 2019-2022 | |
| Amgen INC. | $662.31 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $613.45 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $559.75 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $549.13 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Becton, Dickinson and Company | $512.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $491.79 | 2019-2023 | Steglatro |
| Corcept Therapeutics | $376.93 | 2019-2025 | Korlym |
| Currax Pharmaceuticals LLC | $299.75 | 2020-2024 | Contrave, Onzetra Xsail |
| Ascendis Pharma Endocrinology INC | $216.80 | 2023-2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $215.71 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $201.31 | 2021-2025 | Isturisa, Signifor Lar |
| Grt US Holding, INC. | $181.76 | 2021-2022 | |
| Abiomed | $174.54 | 2024-2025 | Impella |
| Pfizer INC. | $166.13 | 2019-2024 | |
| Genentech USA, INC. | $160.00 | 2022 | |
| Embecta Corp. | $156.44 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Madrigal Pharmaceuticals | $155.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Beta Bionics, INC. | $135.82 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alexion Pharmaceuticals, INC. | $134.85 | 2019-2025 | Strensiq |
| Radius Health, INC. | $124.78 | 2021 | |
| Shire North American Group INC | $121.74 | 2019 | |
| Sequel Med Tech, LLC | $116.06 | 2025 | Twiist |
| Chiesi USA, INC. | $112.04 | 2024-2025 | Mycapssa |
| Antares Pharma, INC. | $92.78 | 2019-2025 | Xyosted |
| Esperion Therapeutics, INC. | $81.26 | 2025 | Nexletol |
| Atricure, INC. | $74.98 | 2024 | |
| Verity Pharmaceuticals INC. | $65.39 | 2024-2025 | Tlando |
| Glaxosmithkline, LLC. | $61.91 | 2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $59.56 | 2023-2024 | |
| Acella Pharmaceuticals, LLC | $54.16 | 2024-2025 | NP Thyroid 60 |
| Eusa Pharma (US) LLC | $50.11 | 2022 | |
| Nevro Corp. | $41.60 | 2022-2023 | Senza |
| Nalpropion Pharmaceuticals LLC | $41.02 | 2019 | |
| Halozyme INC | $40.63 | 2023 | |
| Ibsa Pharma INC. | $33.30 | 2021 | |
| Vivus LLC | $29.78 | 2019-2021 | |
| Averitas Pharma INC. | $23.49 | 2025 | Qutenza |
| Amryt Pharma Holdings LTD | $20.38 | 2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $18.79 | 2021 | |
| Aytu Biopharma, INC. | $18.48 | 2019 | |
| Theracosbio, LLC | $18.38 | 2024 | Brenzavvy |
| Lexicon Pharmaceuticals, INC. | $17.35 | 2023 | Inpefa |
| Ipsen Biopharmaceuticals, INC | $17.22 | 2022 | |
| Lifescan, INC. | $16.73 | 2021 | |
| Kyowa Kirin, INC. | $15.66 | 2024 | Crysvita |
| Acerus Pharmaceuticals Corporation | $15.28 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.05 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.23 | 2019 | |
| Almatica Pharma LLC | $13.76 | 2025 | Teriparatide |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Kowalyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.